Medico Remedies Share Price
39.21-0.29 (-0.73%)
-2.90% past 1 Year
Medico Remedies is in pharmaceutical business. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company's focus is on anti-infective, Beta-Lactums, cephalosporins, antimalarial,
Corporate filings & documents
Announcements
Please find enclosed.
5 days agoPlease find enclosed.
5 days agoPlease find enclosed.
5 days agoPlease find enclosed.
5 days agoPlease find enclosed.
5 days agoPlease find enclosed.
5 days agoPlease find enclosed
2 weeks agoPlease find enclosed
2 weeks agoPlease find enclosed outcome
3 weeks agoPlease find enclosed outcome
3 weeks agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve 1. To consider and approve Unaudited Financial Results for the quarter ended 30th June 2026 along with the Limited Review Report thereon; and2. Any other business with the permission of the Chair.
3 weeks agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve 1. To consider and approve Unaudited Financial Results for the quarter ended 30th June 2026 along with the Limited Review Report thereon; and2. Any other business with the permission of the Chair.
3 weeks agoPlease find enclosed
4 weeks agoPlease find enclosed
4 weeks agoThe Exchange has sought clarification from Medico Remedies Ltd on August 3 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
1 month agoThe Exchange has sought clarification from Medico Remedies Ltd on August 3 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
1 month agoPlease find enclosed
2 months agoPlease find enclosed
2 months agoPlease find enclosed
2 months agoPlease find enclosed
2 months agoPlease find enclosed
3 months agoPlease find enclosed
3 months agoPlease find enclosed
3 months agoPlease find enclosed
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Medico Remedies Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230MH1994PLC077187</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-25 2025-26</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-25 2025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>VIDHI ANKIT SHAH</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>HARESH MEHTA</td></tr> <tr><td>Designation : -</td><td>WHOLE TIME DIRECTOR AND CFO</td></tr></table><div> <br/> Date: 21/05/2026<br/><br/></div>
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Medico Remedies Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230MH1994PLC077187</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-25 2025-26</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-25 2025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>VIDHI ANKIT SHAH</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>HARESH MEHTA</td></tr> <tr><td>Designation : -</td><td>WHOLE TIME DIRECTOR AND CFO</td></tr></table><div> <br/> Date: 21/05/2026<br/><br/></div>
3 months agoPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 21st May 2026 has inter alia considered and approved the following:1. Audited Standalone Financial Results of the Company for the quarter ended 31st March 2026 and Audited Financial Statements for the year ended on 31st March 2026 along with the Auditors Report thereon.We would like to state that M/s. Shah Shroff & Associates Statutory Auditors of the Company have issued audit report with unmodified opinion on the Statements.2. Boards Report and its annexures Management Discussion Analysis (MDA) and Corporate Governance Report of the Company for the financial year ended on 31st March 2026.We wish to inform you that the Board Meeting commenced today at 5:00 P.M and concluded at 5:25 P.M.
3 months agoPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 21st May 2026 has inter alia considered and approved the following:1. Audited Standalone Financial Results of the Company for the quarter ended 31st March 2026 and Audited Financial Statements for the year ended on 31st March 2026 along with the Auditors Report thereon.We would like to state that M/s. Shah Shroff & Associates Statutory Auditors of the Company have issued audit report with unmodified opinion on the Statements.2. Boards Report and its annexures Management Discussion Analysis (MDA) and Corporate Governance Report of the Company for the financial year ended on 31st March 2026.We wish to inform you that the Board Meeting commenced today at 5:00 P.M and concluded at 5:25 P.M.
3 months agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. Audited Financial Results for the quarter ended 31st March 2026 and Audited Financial Statements for the year ended on 31st March 2026; and2. Any other business with the permission of the Chair.
3 months agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. Audited Financial Results for the quarter ended 31st March 2026 and Audited Financial Statements for the year ended on 31st March 2026; and2. Any other business with the permission of the Chair.
3 months agoPlease find enclosed
4 months agoPlease find enclosed
4 months agoPlease find enclosed
6 months agoPlease find enclosed
6 months agoPlease find enclosed
6 months agoPlease find enclosed
6 months agoPlease find enclosed
6 months agoPlease find attached Quarterly Financial Results for the quarter ended 31st December 2025
6 months agoPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 12th February 2026 has inter alia considered and approved the following: 1. Unaudited Standalone Financial Results for the quarter and half year ended 31st December 2025 along with Auditors Limited Review Report thereon; (enclosed)We wish to inform you that the Board Meeting commenced today at 5:00 P.M. and concluded at 05:30 P.M
6 months agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 31st December 2025 along with the Limited Review Report thereon; 2. Any other business with the permission of the Chair
6 months agoPlease find attached requisite disclosure
7 months agoPlease find attached Intimation under Regulation 30 of SEBI LODR Regulations 2025
7 months agoPlease find enclosed disclosure with regards to closure of trading window
8 months agoPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 14th November 2025 has inter alia considered and approved the following: 1. Unaudited Standalone Financial Results for the quarter and half year ended 30th September 2025 alongwith Auditors Limited Review Report thereon; (enclosed)We wish to inform you that the Board Meeting commenced today at 5:00 P.M. and concluded at 06:55 P.M. Kindly take the same on record
9 months agoPlease find attached Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015
9 months agoThe Company has secured government supply order from the Country of Dominican Republic
10 months agoMedico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve We hereby inform you that the meeting of the Board of Directors of the Company will be held on Friday 14th November 2025 inter alia to transact the following business:1. To consider and approve Unaudited Financial Results for the quarter ended 30th September 2025 along with the Limited Review Report thereon; 2. Any other business with the permission of the Chair.Kindly take the same on records.
10 months agoPlease find annexure
11 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Shweta Harshit Mehta & PACs
11 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Harshit Haresh Mehta & PACs
11 months agoAnnual reports
Concalls & investor presentations
Nov 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Corporate Actions
Date
Type
Details
2023-03-16
Split
10:2
Company details
Registered office
1105/1106, 11th Floor Hubtown Solaris, Opp Telli Galli N S Phadke Marg, Andheri (East) Mumbai Maharashtra PIN: 400069 Tel No: 022 26821054 / 1055 / 26837116 Fax No: NULL Email: [email protected] / [email protected] Internet: www.medicoremediesindia.com/www.medicoremediesindia.net/www.tabletandcapsules.com
Registrars
304 Sai Sadan 3rd Floor76 - 78 , Mody Street, Fort,Mumbai – 400001Website: www.cameoindia.comTel: 022 - 22644325; Email id - [email protected] 304 Sai Sadan 3rd Floor 76 - 78 Mody Street Fort PIN: Tel No: 022 - 22644325 Fax No: NULL Email: [email protected] Internet: www.cameoindia.com
Management
Haresh Mehta, Chairman
Harshit Mehta, Managing Director
Rishit Mehta, Whole Time Director
Rita Mehta, Non Independent & Non Executive Director
Deepak Vekaria, Non Executive Independent Director
Bharat Rathod, Non Executive Independent Director
Deepesh Shah, Non Executive Independent Director
Kunal Tushar Vora, Non Executive Independent Director
Anuj Mody, Non Executive Independent Director
Vidhi Ankit Shah, Company Secretary & Compliance Officer
Maheshkumar Darji, Executive Director
Details
BSE 540937
NSE MEDICO
ISIN INE630Y01024